Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 4
2(50.0%)
Early Phase 1
1(25.0%)
Phase 1
1(25.0%)
4Total
Phase 4(2)
Early Phase 1(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07191847Phase 4Recruiting

Assessment of CataClear, Tear Film Stability, Tear Volume, and Dry Eye Symptoms Using Stem Cells Fortified Eye Drops

Role: lead

NCT07187713Phase 4Recruiting

ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases

Role: lead

NCT06787482Phase 1Recruiting

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

Role: lead

NCT03485560Early Phase 1Unknown

Revitalization of Damaged Skin Due to Chronic Skin Diseases

Role: lead

All 4 trials loaded